A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

Sponsor: T.O.A.D. Oncology SA

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT07258407

Patient View

This Phase 1/2 study assesses TD001's safety and preliminary efficacy in men with PSMA-expressing metastatic CRPC. It includes dose escalation to determine Phase 2 doses. Eligible patients must have documented disease progression, measurable lesions, adequate organ function, and prior ARPI treatment. TD001 is administered via IV infusion until disease progression or other criteria are met.

Patient Parameters

Program Overview

This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).

Description

This is a first-in-human, open-label, multicenter Phase 1/2 study with a dose escalation part to determine recommended Phase 2 doses of TD001 for further evaluation in an expansion part of the study. Multiple dosing schedules may be evaluated. The safety and preliminary efficacy endpoints of this study will support dose optimization in this patient population.

Eligibility Criteria

Inclusion Criteria

  • Patient must fully understand the study requirements and voluntarily sign informed consent.
  • PSMA-expressing mCRPC with documented progression based on serum PSA, RECIST 1.1 with PCWG3, and/or bone disease.
  • At least one measurable metastatic lesion per RECIST 1.1.
  • Adequate organ function.
  • Prior orchiectomy and/or ongoing androgen deprivation therapy.
  • Prior treatment with at least one androgen receptor pathway inhibitor (ARPI) drug.

Exclusion Criteria

  • Previous treatment with strontium-89, samarium-153, rhenium-186, rhenium-188, radium-223, or hemi-body irradiation, within 6 months before treatment.
  • Systemic anticancer therapy including an investigational agent within 28 days before treatment.
  • Known hypersensitivity to the components of TD001, its analogs, or excipients.
  • Current dyspnea at rest, other disease requiring continuous oxygen therapy, or history of pneumonitis

Get This Program In Your Inbox

You can sign up and apply your patients for this program.